Re: Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists

2017 ◽  
Vol 87 ◽  
pp. 203 ◽  
Author(s):  
Peter C. Albertsen
Keyword(s):  
Cardiovascular Risk ◽  
Androgen Deprivation Therapy ◽  
Gnrh Antagonist ◽  
Androgen Deprivation ◽  
Meaningful Difference

1295 ANDROGEN DEPRIVATION THERAPY AND MORBID OBESITY: DO THEY SHARE CARDIOVASCULAR RISK THROUGH METABOLIC SYNDROME?

2011 ◽  
Vol 185 (4S) ◽  
Author(s):  
Ary Serpa Neto ◽  
Leonardo O. Reis ◽  
Rodolfo B. dos Reis ◽  
Lucas Nogueira ◽  
Eliney F. Faria ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Morbid Obesity ◽  
Cardiovascular Risk ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation

Androgen deprivation therapy and cardiovascular risk in patients with prostate cancer

2013 ◽  
Vol 18 ◽  
pp. S313
Author(s):  
A. Zapatero ◽  
C. González San Segundo ◽  
A. Boladeras ◽  
A. Gomez Caamaño ◽  
J. Lopez Torrecilla ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cardiovascular Risk ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation

Cardiovascular risk profile of veteran men beginning androgen deprivation therapy

2014 ◽  
Vol 32 (3) ◽  
pp. 99-104
Author(s):  
Lindsay Williams ◽  
Elisabeth Hicks ◽  
Lorna Kwan ◽  
Mark Litwin ◽  
Sally Maliski
Keyword(s):  
Cardiovascular Risk ◽  
Androgen Deprivation Therapy ◽  
Risk Profile ◽  
Androgen Deprivation ◽  
Cardiovascular Risk Profile

scholarly journals Androgen Deprivation Therapy and Cardiovascular Risk

2011 ◽  
Vol 29 (26) ◽  
pp. 3510-3516 ◽  
Author(s):  
Sanoj Punnen ◽  
Matthew R. Cooperberg ◽  
Natalia Sadetsky ◽  
Peter R. Carroll
Keyword(s):  
Cardiovascular Risk ◽  
Propensity Score ◽  
Androgen Deprivation Therapy ◽  
Local Treatment ◽  
Local Therapy ◽  
National Registry ◽  
Androgen Deprivation ◽  
Treatment Selection ◽  
Increased Risk ◽  
Significant Difference

Purpose The potential association between androgen deprivation therapy (ADT) and cardiovascular mortality (CVM) remains controversial. This study assessed mortality outcomes in a large national registry to further elucidate the association between treatment selection and cause of mortality. Patients and Methods A total of 7,248 men in the CaPSURE registry were analyzed. Treatment was categorized as local only, primary ADT monotherapy, local treatment plus ADT, and watchful waiting/active surveillance (WW/AS). Competing hazards survival analysis was performed for prostate cancer–specific mortality (PCSM), CVM, and all-cause mortality. A propensity score–adjusted and a propensity-matched analysis were undertaken to adjust for imbalances in covariates among men receiving various treatments. Results Patients treated with ADT or WW/AS had a higher likelihood of PCSM than those treated with local therapy alone. Patients treated with primary ADT had an almost two-fold greater likelihood of CVM (HR, 1.94; 95% CI, 1.29 to 2.97) than those treated with local therapy alone; however, patients treated with WW/AS had a greater than two-fold increased risk of CVM (HR, 2.46; 95% CI, 1.53 to 3.95). A propensity-matching algorithm in a subset of 1,391 patients was unable to find a significant difference in CVM between those who did or did not receive ADT. Conclusion Patients matched on propensity to receive ADT did not show an association between ADT and CVM. This suggests that potential unmeasured variables affecting treatment selection may confound the relationship between ADT use and cardiovascular risk. However, an association may yet exist, because the propensity score could not include all known risk factors for CVM.

scholarly journals Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer

Medicine ◽  
2016 ◽  
Vol 95 (24) ◽  
pp. e3873 ◽  
Author(s):  
Lucie-Marie Scailteux ◽  
Florian Naudet ◽  
Quentin Alimi ◽  
Sébastien Vincendeau ◽  
Emmanuel Oger
Keyword(s):  
Prostate Cancer ◽  
Cardiovascular Risk ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation
Sign in / Sign up

Export Citation Format

Share Document